Altris AI Introduces Next-Generation Fluids and GA Quantification Features

Altris AI, a pioneering force in artificial intelligence for OCT scan analysis, has unveiled additional quantification features for Fluids and Geographic Atrophy (GA) tracking on its web platform. Altris AI currently detects over 70 retina pathologies and biomarkers. However, we have decided to enhance its capabilities by adding additional Fluids and GA quantification and tracking functionalities, recognizing that eye care specialists frequently work with these conditions.

These advancements empower eye care professionals (ECPs) with cutting-edge tools for diagnosing and managing retinal diseases. By integrating AI-driven quantitative tracking and progression monitoring, Altris AI enables specialists to deliver more personalized and effective treatments, ultimately enhancing patient outcomes.

Fluids Quantification and Progression Tracking

The presence of fluids such as Intraretinal Cystoid Fluid (IRC), Diffuse Edema, Subretinal Fluid (SRF), and Serous Retinal Pigment Epithelium (RPE) Detachment are critical biomarkers for conditions like nAMD, DME, DR, and RVO. Accurate detection, quantification, and tracking of these fluids are essential for monitoring disease activity, evaluating treatment efficacy, and making informed prognoses.

We created specialized more detailed functions which detect these biomarkers for more specific and accurate tracking. The AI algorithm was additionally trained to work directly with fluids taking into account the importance of these biomarkers for accurate diagnostics.

Altris AI’s advanced algorithms, trained on millions of OCT scans, provide precise and objective fluid analysis. Each of the four fluid types is localized and color-coded for clarity. Quantitative metrics such as volume, area, and ETDRS grids (1, 3, and 6 mm) are calculated and presented in mm3 or nanoliters for comprehensive evaluation. The Progression Tracking feature offers historical trend analysis with intuitive visualizations through graphs and percentages. For instance, if Cystoid Fluid (IRC) increases in volume, ECPs can immediately identify and address the change.

Precision in Geographic Atrophy (GA) Monitoring

Recent advancements in GA treatment have led to a growing need for large-scale screening in clinical practice. However, this increased demand often means higher workloads and less time for in-depth analysis. 

The platform facilitates automated detection, quantification, and tracking of GA by analyzing key biomarkers: Pigment Epithelium (RPE) atrophy, Hypertransmission, Neurosensory Retina Atrophy, and Ellipsoid Zone (EZ) disruption. These biomarkers are color-coded for easier identification. 

We assess GA using three key criteria:

1. Overlapping region of 3 biomarkers: Hypertransmission, RPE Atrophy, and Neurosensory Retina Atrophy (referred as the GA zone).
2. The shortest distance from the Fovea center to the GA zone.
3. Percentage of the GA zone covering the 1 mm, 3 mm, and 6 mm ETDRS grid areas.

We also improved the accuracy of a critical step in our AI pipeline: the fovea and central scan detection. Altris AI’s updated model is much more robust in detecting fovea zone and central scan now. Especially in cases when the center cannot be distinguished due to pathology presence or other reasons, the model is trained to analyze the whole surface and find reference locations from which a central scan could be determined. The new model can find an accurate center in 95% of cases, in other situations, it can efficiently estimate the center location (as opposed to a simple analysis flow used by ECPs where the geometrical center is selected). This advancement significantly enhances the precision of GA detection.

Further Progression Tracking enhances GA management by visualizing changes over time, supporting timely and accurate treatment decisions. By streamlining workflows and providing actionable insights, this feature helps ECPs make informed choices and potentially preserve vision in GA patients.

Dr. Maria Znamenska, MD, PhD, and a Chief Medical Officer at Altris AI, commented:

“We listened to our clients and introduced Fluids and GA tracking features. In 2025, eye care specialists will have the tools to combine their expertise with next-generation AI technology to effectively tackle conditions that threaten vision. Our formula is simple: detect, quantify, and track fluids, GA, and 70+ retina pathologies and biomarkers for better patient outcomes.”

About Altris AI

Altris AI is an artificial intelligence platform for OCT analysis that detects the widest range of retina pathologies and biomarkers on the market – more than 70. Leading the way in AI innovation, Altris AI provides transformative solutions that enhance the diagnosis, treatment, and monitoring of retinal diseases, enabling eye care professionals to deliver exceptional patient care.